A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer.
Not Applicable
Recruiting
- Conditions
- women with HER2-positive and hormone receptor-positive breast cancer
- Registration Number
- JPRN-UMIN000009108
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Other active malignancies 2. Hemorrhagic diathesis 3. History of cardiac infarction, valvular diseases of the heart and severe cardiac disfunction 4. Liver cirrhosis 5. Other medical conditions that could limit a patient's ability to undertake study therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method